SOPH · SOPHiA GENETICS SA
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-13 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.43 to $7.62, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,000 |
| 2026-08-12 | Menu Philippe |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-08-10 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.50 to $7.80, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
8,500 |
| 2026-08-07 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.56, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
10,000 |
| 2026-08-07 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.20 to $7.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
20,000 |
| 2026-08-07 | Verma Abhimanyu |
Chief Technology Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
5,000 |
| 2026-08-07 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.08, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
7,000 |
| 2026-08-07 | Xu Zhenyu |
Chief Scientific Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 975,041 derivative share options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
7,000 |
| 2026-08-07 | Xu Zhenyu |
Chief Scientific Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
7,000 |
| 2026-08-05 | Xu Zhenyu |
Chief Scientific Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
3,000 |
| 2026-08-05 | Xu Zhenyu |
Chief Scientific Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 982,041 derivative share options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
3,000 |
| 2026-08-05 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
3,000 |
| 2026-08-04 | Verma Abhimanyu |
Chief Technology Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.95 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-08-04 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
10,000 |
| 2026-08-04 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
20,000 |
| 2026-07-27 | Menu Philippe |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.57 to $5.83, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-07-21 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.60 to $6.72, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
20,000 |
| 2026-07-20 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
4,581 |
| 2026-07-20 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
4,581 |
| 2026-07-20 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
19,800 |
| 2026-07-20 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,581 |
| 2026-07-13 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.54 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,000 |
| 2026-07-13 | Menu Philippe |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.55 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-07-10 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.53 to $5.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
8,500 |
| 2026-07-07 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. |
Ordinary Shares
|
17,685 |
| 2026-07-06 | Valente Manuela |
Chief People Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.95 to $5.34, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
4,241 |
| 2026-07-06 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
22,486 |
| 2026-07-06 | Menu Philippe |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.44, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
7,393 |
| 2026-07-06 | Xu Zhenyu |
Chief Scientific Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
7,393 |
| 2026-07-06 | Puylaert Kevin |
Chief Sales Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. |
Ordinary Shares
|
138 |
| 2026-07-06 | Puylaert Kevin |
Chief Sales Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. |
Ordinary Shares
|
31 |
| 2026-07-06 | Muken Ross |
President |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
9,838 |
| 2026-07-06 | Puylaert Kevin |
Chief Sales Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on July 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades. |
Ordinary Shares
|
47 |
| 2026-07-06 | Verma Abhimanyu |
Chief Technology Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.41, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,285 |
| 2026-07-06 | CARDOZA GEORGE |
President & COO, Lab Ops |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
1,592 |
| 2026-06-30 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
45,419 |
| 2026-06-30 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
19,650 |
| 2026-06-30 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
45,419 |
| 2026-06-30 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
200 |
| 2026-06-30 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,646,057 derivative stock options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
45,419 |
| 2026-06-29 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
18,060 |
| 2026-06-29 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,691,476 derivative stock options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
18,060 |
| 2026-06-29 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
350 |
| 2026-06-29 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
18,060 |
| 2026-06-26 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↓
Filing footnotes — Share Option (Right to Buy) (Direct)
The share options are fully vested and exercisable. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,709,536 derivative stock options across all remaining grant tranches with varying exercise prices. |
Share Option (Right to Buy)
|
31,940 |
| 2026-06-26 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.70 to $5.78, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
18,129 |
| 2026-06-26 | Camblong Jurgi |
Director, Chief Executive Officer |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
Ordinary Shares
|
31,940 |
| 2026-06-26 | Camblong Jurgi |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.80 to $5.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
31,940 |
| 2026-06-25 | Menu Philippe |
Chief Medical Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.30 to $5.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-06-25 | Verma Abhimanyu |
Chief Technology Officer |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.31 to $5.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
6,944 |